Prescription Description
| Prescription ID | TCMF2546 |
| Pinyin Name | Yi Qi Tiao Jiang Ya Tang |
| Chinese Name | 益气调肝降脂汤 |
| English Name | Qi and Liver Modulating Decoction |
| Function Description | |
| Indications | None |
| Disease ICD-11 Category | |
| Human Tissues Associated with Indication | |
| Reference | Chinese Classical Prescriptions |
| Reference Book/link | ISBN 7-5023-3930-2 |
Prescription Components
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH981 | Astragalus membranaceus | 黄芪 | TCMH981 | ITSAK2981-14 |
| TCMH2507 | Epimedium brevicornum | 淫羊藿 | TCMH2507 | AY362429 |
| TCMH2121 | Semen astragali complanati | 潼蒺藜 | TCMH2121 | |
| TCMH73 | Tribulus terrestris | 白蒺藜 | TCMH73 | ITSAJ4258-14 |
| TCMH31 | Morinda officinalis | 巴戟天 | TCMH31 | ITSAJ4459-14 |
| TCMH761 | Cinnamomum cassia | 桂枝 | TCMH761 | GQ255631 |
| TCMH810 | Paeonia albiflora | 杭芍 | TCMH810 | MF096543 |
| TCMH421 | Angelica sinensis | 当归 | TCMH421 | ITSAF173-14 |
| TCMH305 | Cnidium officinale | 川芎 | TCMH305 | ITSAP4207-14 |
| TCMH819 | Polygonum multiflorum | 何首乌 | TCMH819 | ITSAL419-14 |
| TCMH1321 | Os draconis | 龙骨 | TCMH1321 | |
| TCMH1525 | Crassostrea gigas | 牡蛎 | TCMH1525 | BCMOL364-12 |
| TCMH1966 | Rehmannia glutinosa | 熟地黄 | TCMH1966 | ITSAH4578-14 |
| TCMH695 | Uncaria rhynchophylla | 钩藤 | TCMH695 | ITSAM939-14 |
Targeted Human Proteins by the Ingredients of Prescription
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT102 | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | Hydrolase | P24666 |
| TCMT103 | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | Hydrolase | P10586 |
| TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT139 | CA6 | Carbonic anhydrase VI | Lyase | P23280 |
| TCMT140 | CA5B | Carbonic anhydrase VB | Lyase | Q9Y2D0 |
| TCMT141 | CA5A | Carbonic anhydrase VA | Lyase | P35218 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT143 | CA3 | Carbonic anhydrase III | Lyase | P07451 |
| TCMT150 | RORC | Nuclear receptor ROR-gamma | Nuclear receptor | P51449 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT161 | HCAR2 | Hydroxycarboxylic acid receptor 2 | GPCR | Q8TDS4 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT164 | PTGS1 | Cyclooxygenase-1 | Oxidoreductase | P23219 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT206 | CYP2A6 | Cytochrome P450 2A6 | Oxidoreductase | P11509 |
| TCMT208 | MAOA | Monoamine oxidase A | Oxidoreductase | P21397 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT268 | CYP2A13 | Cytochrome P450 2A13 | Oxidoreductase | Q16696 |
| TCMT27 | DRD1 | Dopamine D1 receptor | GPCR | P21728 |
| TCMT295 | MMP1 | Matrix metalloproteinase-1 | Hydrolase | P03956 |
| TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
| TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
| TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
| TCMT30 | PTGS2 | Cyclooxygenase-2 | Oxidoreductase | P35354 |
| TCMT306 | MMP2 | Matrix metalloproteinase-2 | Hydrolase | P08253 |
| TCMT321 | MMP9 | Matrix metalloproteinase 9 | Hydrolase | P14780 |
| TCMT329 | NQO2 | Quinone reductase 2 | Oxidoreductase | P16083 |
| TCMT332 | AOC3 | Amine oxidase, copper containing | Oxidoreductase | Q16853 |
| TCMT355 | CSNK1D | Casein kinase I delta | Kinase | P48730 |
| TCMT38 | DRD2 | Dopamine D2 receptor | GPCR | P14416 |
| TCMT417 | DYRK2 | Dual-specificity tyrosine-phosphorylation regulated kinase 2 | Kinase | Q92630 |
| TCMT458 | HASPIN | Serine/threonine-protein kinase haspin | Kinase | Q8TF76 |
| TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
| TCMT473 | PIM3 | Serine/threonine-protein kinase PIM3 | Kinase | Q86V86 |
| TCMT560 | F10 | Coagulation factor X | Unclassified | P00742 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
| TCMT599 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Transferase | P61088 |
| TCMT614 | EGLN1 | Egl nine homolog 1 | Oxidoreductase | Q9GZT9 |
| TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT690 | HDAC3 | Histone deacetylase 3 | Hydrolase | O15379 |
| TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
| TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
| TCMT729 | PIK3CA | PI3-kinase p110-alpha subunit | Transferase | P42336 |
| TCMT730 | PIK3CB | PI3-kinase p110-beta subunit | Transferase | P42338 |
| TCMT751 | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Kinase | Q13627 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT763 | DYRK3 | Dual-specificity tyrosine-phosphorylation regulated kinase 3 | Kinase | O43781 |
| TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
| TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
| TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
| TCMT814 | CLK1 | Dual specificty protein kinase CLK1 | Kinase | P49759 |
| TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT829 | NISCH | Nischarin | Unclassified | Q9Y2I1 |
| TCMT831 | DYRK4 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 | Kinase | Q9NR20 |
| TCMT832 | DYRK1B | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Kinase | Q9Y463 |
| TCMT907 | FDPS | Farnesyl diphosphate synthase | Lyase | P14324 |
Targeted Pathogenic Microbes by the Ingredients of Prescription
| Target ID | Target Name |
|---|---|
| TCMT1170 | Enterobacter cloacae |
| TCMT1175 | Human immunodeficiency virus |
| TCMT1176 | Streptococcus pneumoniae |
| TCMT1178 | Actinomyces viscosus |
| TCMT1181 | Mycobacterium tuberculosis H37Ra |
| TCMT1182 | Streptococcus sanguinis |
| TCMT1189 | Pseudomonas fluorescens |
| TCMT1190 | Plasmodium falciparum (isolate FcB1 / Columbia) |
| TCMT1208 | Escherichia coli K12 |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1210 | Streptococcus sobrinus |
| TCMT1211 | Fusobacterium nucleatum |
| TCMT1212 | Verticillium dahliae |
| TCMT1213 | Neisseria gonorrhoeae |
| TCMT1215 | Pseudomonas aeruginosa PAO1 |
| TCMT1218 | Staphylococcus aureus |
| TCMT1222 | Plasmodium falciparum D6 |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1243 | Aspergillus flavus |
| TCMT1245 | Phytophthora cactorum |
| TCMT1246 | Escherichia coli |
| TCMT1251 | Candida albicans |
| TCMT1253 | Penicillium chrysogenum |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1321 | Staphylococcus hominis |
| TCMT1343 | Staphylococcus simulans |
| TCMT1344 | Staphylococcus sciuri |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1361 | Neisseria meningitidis |
| TCMT1370 | Prevotella melaninogenica |
| TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
| TCMT1408 | Colletotrichum gloeosporioides |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1439 | Mycobacterium smegmatis |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1444 | Fusarium oxysporum |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1464 | Hepatitis B virus |
| TCMT1465 | Entamoeba histolytica |
Gene Ontology Associated to Targeted Human Proteins
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 14.7675 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 13.885 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, FDPS, FUT7, NISCH, PIK3CA, PPARA, PTGS1, PTGS2, XDH | 10.0029 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD2, ESR1, FABP3, FABP4, FDPS, FUT7, HSD17B1, PIK3CA, PIK3CB, PPARA, PTGS1, PTGS2 | 9.31455 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DRD2, FABP3, PPARA | 8.09407 |
| [BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CLK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD1, DRD2, DYRK1A, DYRK1B, DYRK2, DYRK3, ESR1, F10, FABP3, FABP4, FDPS, FUT7, HASPIN, HSD17B1, MAOA, MMP1, MMP2, MMP9, NISCH, NQO2, PIK3CA, PIK3CB, PPARA, PTGS1, PTGS2, RORC, XDH | 8.01715 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, BCL2, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 6.97935 |
| [BP] GO:0019369 | arachidonic acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGS1, PTGS2 | 6.82229 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DRD2, FABP3, PPARA | 6.76417 |
| [BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, ALPL, BCL2, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CLK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD1, DRD2, DYRK1A, DYRK1B, DYRK2, DYRK3, ESR1, F10, FABP3, FABP4, FDPS, FUT7, HASPIN, HSD17B1, MAOA, MMP1, MMP2, NQO2, PIK3CA, PIK3CB, PPARA, PTGS1, PTGS2, RORC, XDH | 6.70076 |
| [BP] GO:0044255 | cellular lipid metabolic process | ACHE, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD2, FABP3, FABP4, FDPS, FUT7, PIK3CA, PIK3CB, PPARA, PTGS1, PTGS2 | 6.38448 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, BCL2, CA3, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, ESR1, FABP3, MMP2, MMP9, PIK3CA, PPARA, PTGS2, RORC | 6.30014 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 5.65819 |
| [BP] GO:0033559 | unsaturated fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGS1, PTGS2 | 5.19262 |
| [BP] GO:0001676 | long-chain fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGS1, PTGS2 | 5.12976 |
| [BP] GO:0006690 | icosanoid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGS1, PTGS2 | 5.02473 |
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, ESR1, FDPS, HSD17B1 | 4.83571 |
| [BP] GO:0032228 | regulation of synaptic transmission, GABAergic | ADORA1, CA2, CA7, DRD2, NISCH | 4.7932 |
| [BP] GO:0006805 | xenobiotic metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, NQO2, PTGS1, RORC | 4.78681 |
| [BP] GO:0014070 | response to organic cyclic compound | ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, ESR1, PTGS2, RORC | 4.44861 |
| [BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.36173 |
| [BP] GO:0006631 | fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, PPARA, PTGS1, PTGS2 | 4.26927 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, BCL2, CA12, CA2, CA7, CYP19A1, CYP1A1, CYP1B1, DRD1, DRD2, ESR1, F10, FABP3, FABP4, HCAR2, HSD17B1, MAOA, NISCH, PIK3CA, PIK3CB, PPARA, PTGS1, PTGS2, XDH | 4.22899 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, BCL2, CA2, CA3, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, ESR1, FABP3, FABP4, MMP2, PIK3CA, PPARA, PTGS2, RORC | 4.19256 |
| [BP] GO:1901568 | fatty acid derivative metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGS1, PTGS2 | 3.98988 |
| [BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, FDPS, HSD17B1, PIK3CA, PIK3CB, PTGS1, PTGS2 | 3.94353 |
| [BP] GO:0010035 | response to inorganic substance | AKR1B1, BCL2, CA2, CYP1A1, CYP1A2, CYP1B1, DRD2, FABP4, MMP9, PTGS2 | 3.71711 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1 | 3.6686 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD17B1, MAOA, NQO2, PTGS1, PTGS2, XDH | 3.5579 |
| [BP] GO:0009698 | phenylpropanoid metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.55546 |
| [BP] GO:0009804 | coumarin metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.55546 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1 | 3.54862 |
| [BP] GO:0050805 | negative regulation of synaptic transmission | ACHE, ADORA1, DRD1, DRD2, PTGS2 | 3.46564 |
| [BP] GO:0042221 | response to chemical | AKR1B1, ALPL, BCL2, CA2, CA3, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, ESR1, FABP3, FABP4, MMP2, MMP9, PIK3CA, PPARA, PTGS2, RORC | 3.44356 |
| [BP] GO:0050806 | positive regulation of synaptic transmission | ADORA1, CA2, CA7, DRD1, DRD2, PTGS2 | 3.43443 |
| [BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, DRD1, DRD2, F10, HCAR2, MMP9, PIK3CA, PIK3CB, PTGS2, XDH | 3.415 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CYP19A1, CYP1A1, CYP1B1, DRD2, ESR1, HCAR2, HSD17B1 | 3.415 |
| [BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, DRD1, DRD2, F10, HCAR2, MMP9, PIK3CA, PIK3CB, PTGS2, XDH | 3.39774 |
| [BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, FABP3, PPARA, PTGS2 | 3.3047 |
| [BP] GO:0006811 | None | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DRD1, DRD2, FABP3, PPARA | 3.3047 |
| [BP] GO:0050804 | modulation of chemical synaptic transmission | ACHE, ADORA1, CA2, CA7, DRD1, DRD2, NISCH, PTGS2 | 3.28419 |
| [BP] GO:0099177 | regulation of trans-synaptic signaling | ACHE, ADORA1, CA2, CA7, DRD1, DRD2, NISCH, PTGS2 | 3.28419 |
| [BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, BCL2, CYP19A1, CYP1A1, CYP1B1, DRD1, DRD2, FDPS, MAOA | 3.24884 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, DRD1, ESR1, FABP3, MMP2, PPARA, PTGS2 | 3.21489 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.14146 |
| [BP] GO:0018107 | peptidyl-threonine phosphorylation | BCL2, CLK1, CSNK2A1, DYRK1A, HASPIN | 3.14146 |
| [BP] GO:0018958 | None | AKR1B1, BCL2, DRD1, DRD2, MAOA | 3.14146 |
| [BP] GO:0010038 | response to metal ion | BCL2, CA2, CYP1A1, CYP1A2, DRD2, FABP4, MMP9, PTGS2 | 3.14146 |
| [BP] GO:0006796 | phosphate-containing compound metabolic process | ACHE, ALPL, BCL2, CA3, CLK1, CSNK2A1, DRD1, DRD2, DYRK1A, DYRK1B, DYRK2, DYRK3, FDPS, HASPIN, PIK3CA, PIK3CB, PTGS2, XDH | 3.1281 |
| [BP] GO:0032846 | positive regulation of homeostatic process | CA2, CA7, DRD1, DRD2, HCAR2, PIK3CB, PTGS2 | 3.0991 |
| [BP] GO:0008217 | None | ADORA1, DRD2, NISCH, PPARA, PTGS1, PTGS2 | 3.02037 |
| [BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, ESR1, FABP3, PTGS2, RORC | 3.01186 |
| [BP] GO:0018210 | peptidyl-threonine modification | BCL2, CLK1, CSNK2A1, DYRK1A, HASPIN | 2.9913 |
| [BP] GO:0009056 | catabolic process | ACHE, ADORA1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, FABP3, FABP4, FUT7, MAOA, MMP1, MMP2, MMP9, PIK3CB, XDH | 2.88986 |
| [BP] GO:0006793 | phosphorus metabolic process | ACHE, ALPL, BCL2, CA3, CLK1, CSNK2A1, DRD1, DRD2, DYRK1A, DYRK1B, DYRK2, DYRK3, FDPS, HASPIN, PIK3CA, PIK3CB, PTGS2, XDH | 2.8786 |
| [BP] GO:0032844 | regulation of homeostatic process | ADORA1, BCL2, CA2, CA7, DRD1, DRD2, HCAR2, PIK3CB, PTGS2 | 2.84637 |
| [BP] GO:0032787 | None | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, PPARA, PTGS1, PTGS2 | 2.82239 |
| [BP] GO:0006584 | None | AKR1B1, DRD1, DRD2, MAOA | 2.81561 |
| [BP] GO:0009712 | None | AKR1B1, DRD1, DRD2, MAOA | 2.81561 |
| [BP] GO:0019216 | regulation of lipid metabolic process | ADORA1, CYP1A1, FABP3, FDPS, HCAR2, PPARA, PTGS2, RORC | 2.79554 |
| [BP] GO:0030334 | regulation of cell migration | ADORA1, ADORA3, BCL2, CYP19A1, CYP1B1, DRD1, DRD2, F10, MMP9, NISCH, PTGS2 | 2.7756 |
| [BP] GO:0001666 | response to hypoxia | ADORA1, BCL2, CYP1A1, DRD2, MMP2, PPARA, PTGS2 | 2.7756 |
| [BP] GO:0048878 | chemical homeostasis | AKR1B1, BCL2, CA12, CA2, CA7, DRD1, DRD2, ESR1, FABP3, FABP4, PIK3CA, PIK3CB | 2.7343 |
| [BP] GO:0030336 | None | ADORA1, ADORA3, BCL2, CYP19A1, CYP1B1, DRD2, NISCH | 2.73059 |
| [BP] GO:0036293 | response to decreased oxygen levels | ADORA1, BCL2, CYP1A1, DRD2, MMP2, PPARA, PTGS2 | 2.71414 |
| [BP] GO:0009611 | response to wounding | ACHE, ADORA3, BCL2, CYP1A1, DRD2, PPARA | 2.65189 |
| [BP] GO:0010646 | regulation of cell communication | ACHE, ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, DRD1, DRD2, DYRK1A, DYRK2, DYRK3, ESR1, F10, HCAR2, MMP9, NISCH, PIK3CA, PIK3CB, PTGS2, XDH | 2.62793 |
| [BP] GO:0097164 | None | ACHE, AKR1B1, CSNK2A1, DRD1, DRD2, MAOA | 2.62013 |
| [BP] GO:0032225 | None | DRD1, DRD2, PTGS2 | 2.60778 |
| [BP] GO:2000146 | None | ADORA1, ADORA3, BCL2, CYP19A1, CYP1B1, DRD2, NISCH | 2.6033 |
| [BP] GO:2000145 | regulation of cell motility | ADORA1, ADORA3, BCL2, CYP19A1, CYP1B1, DRD1, DRD2, F10, MMP9, NISCH, PTGS2 | 2.57685 |
| [BP] GO:0048511 | rhythmic process | BCL2, CSNK2A1, DRD2, DYRK1A, ESR1, PPARA, RORC | 2.57685 |
| [BP] GO:0017144 | drug metabolic process | ACHE, AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, DRD1, DRD2, MAOA | 2.5754 |
| [BP] GO:0023051 | regulation of signaling | ACHE, ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, DRD1, DRD2, DYRK1A, DYRK2, DYRK3, ESR1, F10, HCAR2, MMP9, NISCH, PIK3CA, PIK3CB, PTGS2, XDH | 2.57481 |
| [BP] GO:0009636 | response to toxic substance | AKR1B1, ALPL, BCL2, CA3, CYP1A1, CYP1B1, DRD1, DRD2 | 2.5583 |
| [BP] GO:0070482 | response to oxygen levels | ADORA1, BCL2, CYP1A1, DRD2, MMP2, PPARA, PTGS2 | 2.52578 |
| [BP] GO:0071702 | None | ADORA1, CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DRD1, DRD2, FABP3, NISCH, PPARA | 2.49579 |
| [BP] GO:0051271 | None | ADORA1, ADORA3, BCL2, CYP19A1, CYP1B1, DRD2, NISCH | 2.48643 |
| [BP] GO:0006950 | response to stress | ACHE, ADORA1, ADORA3, AKR1B1, BCL2, CA2, CA3, CA9, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, DYRK2, MMP2, MMP9, PIK3CA, PIK3CB, PPARA, PTGS1, PTGS2 | 2.47991 |
| [BP] GO:0048871 | multicellular organismal homeostasis | ADORA1, AKR1B1, DRD1, DRD2, PIK3CA | 2.43841 |
| [BP] GO:1902531 | regulation of intracellular signal transduction | ADORA1, AKR1B1, BCL2, CSNK2A1, CYP1B1, DRD2, DYRK1A, DYRK2, DYRK3, ESR1, F10, MMP9, PIK3CA, PIK3CB, PTGS2, XDH | 2.42399 |
| [BP] GO:0051966 | regulation of synaptic transmission, glutamatergic | ADORA1, DRD1, DRD2, PTGS2 | 2.38253 |
| [BP] GO:0040013 | None | ADORA1, ADORA3, BCL2, CYP19A1, CYP1B1, DRD2, NISCH | 2.37764 |
| [BP] GO:2000021 | regulation of ion homeostasis | ADORA1, BCL2, CA2, CA7, DRD1, DRD2 | 2.36411 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.36254 |
| [BP] GO:0040012 | regulation of locomotion | ADORA1, ADORA3, BCL2, CYP19A1, CYP1B1, DRD1, DRD2, F10, MMP9, NISCH, PTGS2 | 2.31624 |
| [BP] GO:0051270 | regulation of cellular component movement | ADORA1, ADORA3, BCL2, CYP19A1, CYP1B1, DRD1, DRD2, F10, MMP9, NISCH, PTGS2 | 2.30666 |
| [BP] GO:0042493 | response to drug | AKR1B1, BCL2, CA3, CA9, CYP1A1, CYP1B1, DRD1, DRD2, FABP3, PTGS2 | 2.28579 |
| [BP] GO:0048522 | positive regulation of cellular process | ACHE, ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, DRD1, DRD2, DYRK1A, DYRK1B, DYRK2, ESR1, F10, FABP3, HCAR2, MMP1, MMP2, MMP9, PIK3CA, PIK3CB, PPARA, PTGS2, RORC, XDH | 2.27973 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.20871 |
| [BP] GO:0070887 | cellular response to chemical stimulus | AKR1B1, ALPL, BCL2, CYP1A1, CYP1A2, CYP1B1, DRD1, ESR1, FABP4, MMP2, MMP9, PIK3CA, PTGS2, RORC | 2.20488 |
| [BP] GO:0050896 | response to stimulus | ACHE, ADORA1, ADORA3, AKR1B1, ALPL, BCL2, CA2, CA3, CA6, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, DYRK2, ESR1, F10, FABP3, FABP4, MMP2, MMP9, PIK3CA, PIK3CB, PPARA, PTGS1, PTGS2, RORC | 2.16616 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1 | 2.16616 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.16616 |
| [BP] GO:0032879 | regulation of localization | ACHE, ADORA1, ADORA3, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, DRD1, DRD2, DYRK2, F10, HCAR2, MMP9, NISCH, PIK3CB, PPARA, PTGS2 | 2.14986 |
| [BP] GO:0006979 | response to oxidative stress | AKR1B1, BCL2, CA3, CYP1B1, MMP9, PTGS1, PTGS2 | 2.14973 |
| [BP] GO:0043271 | negative regulation of ion transport | ADORA1, BCL2, DRD2, MMP9, PTGS2 | 2.13626 |
| [BP] GO:0032502 | developmental process | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, DYRK1A, DYRK1B, DYRK3, ESR1, FABP4, FUT7, MMP2, MMP9, PIK3CA, PIK3CB, PPARA, PTGS2, RORC | 2.13626 |
| [BP] GO:0009987 | cellular process | ACHE, ADORA1, ADORA3, AKR1B1, ALPL, BCL2, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CLK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD1, DRD2, DYRK1A, DYRK1B, DYRK2, DYRK3, ESR1, F10, FABP3, FABP4, FDPS, FUT7, HASPIN, HCAR2, HSD17B1, MAOA, MMP1, MMP2, MMP9, NISCH, NQO2, PIK3CA, PIK3CB, PPARA, PTGS1, PTGS2, RORC, XDH | 2.13619 |
| [BP] GO:0033031 | positive regulation of neutrophil apoptotic process | HCAR2, PIK3CB | 2.12416 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.12416 |
| [BP] GO:0071407 | cellular response to organic cyclic compound | ALPL, CYP1A1, CYP1B1, DRD1, ESR1, PTGS2, RORC | 2.10698 |
| [BP] GO:0071248 | cellular response to metal ion | CYP1A1, CYP1A2, FABP4, MMP9, PTGS2 | 2.05447 |
| [BP] GO:0048661 | positive regulation of smooth muscle cell proliferation | AKR1B1, MMP2, MMP9, PTGS2 | 2.03125 |
| [BP] GO:0048856 | anatomical structure development | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, DYRK1A, DYRK1B, ESR1, MMP9, PIK3CA, PPARA, PTGS2, RORC | 2.0209 |
| [BP] GO:0042592 | homeostatic process | ADORA1, AKR1B1, BCL2, CA12, CA2, CA7, DRD1, DRD2, ESR1, FABP3, FABP4, PIK3CA, PIK3CB | 2.00795 |
| [BP] GO:0033032 | regulation of myeloid cell apoptotic process | BCL2, HCAR2, PIK3CB | 2.00795 |
| [BP] GO:0042417 | None | DRD1, DRD2, MAOA | 2.00795 |
| [CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD1, PTGS1, PTGS2 | 1.65177 |
| [CC] GO:0044444 | cytoplasmic part | ACHE, ADORA1, AKR1B1, BCL2, CA1, CA2, CA3, CA4, CA5A, CA5B, CA7, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD1, DRD2, DYRK2, DYRK3, ESR1, F10, FABP3, FABP4, FDPS, FUT7, HSD17B1, MAOA, MMP2, MMP9, NISCH, NQO2, PIK3CA, PIK3CB, PTGS1, PTGS2, XDH | 1.48523 |
| [CC] GO:0043227 | membrane-bounded organelle | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA1, CA2, CA4, CA5A, CA5B, CA6, CLK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, DYRK1A, DYRK1B, DYRK2, DYRK3, ESR1, FABP3, FABP4, FDPS, FUT7, HASPIN, MAOA, MMP2, MMP9, NISCH, NQO2, PIK3CB, PPARA, PTGS1, PTGS2, RORC, XDH | 1.32517 |
| [CC] GO:0044432 | endoplasmic reticulum part | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD1, F10, PTGS1, PTGS2 | 1.22752 |
| [CC] GO:0031233 | None | CA4, F10 | 1.01145 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 21.191 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 13.885 |
| [MF] GO:0046914 | transition metal ion binding | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DYRK2, ESR1, MMP1, MMP2, MMP9, NQO2, PPARA, RORC, XDH | 13.5747 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 12.4663 |
| [MF] GO:0043167 | ion binding | ACHE, ALPL, CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CLK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD1, DRD2, DYRK1A, DYRK1B, DYRK2, DYRK3, ESR1, F10, FABP3, FABP4, FDPS, HASPIN, HSD17B1, MMP1, MMP2, MMP9, NISCH, NQO2, PIK3CA, PIK3CB, PPARA, PTGS1, PTGS2, RORC, XDH | 12.391 |
| [MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, ALPL, CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CLK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DYRK1A, DYRK1B, DYRK2, DYRK3, F10, FDPS, FUT7, HASPIN, HSD17B1, MAOA, MMP1, MMP2, MMP9, NQO2, PIK3CA, PIK3CB, PTGS1, PTGS2, XDH | 9.0577 |
| [MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 | 8.33498 |
| [MF] GO:0043169 | cation binding | ACHE, ALPL, CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DRD1, DRD2, DYRK2, DYRK3, ESR1, F10, FDPS, MMP1, MMP2, MMP9, NQO2, PPARA, PTGS1, PTGS2, RORC, XDH | 8.01715 |
| [MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, MMP1, MMP2, MMP9, NQO2, PPARA, RORC | 7.40825 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 7.01905 |
| [MF] GO:0046872 | metal ion binding | ALPL, CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, DYRK2, DYRK3, ESR1, F10, FDPS, MMP1, MMP2, MMP9, NQO2, PPARA, PTGS1, PTGS2, RORC, XDH | 6.12623 |
| [MF] GO:0020037 | heme binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGS1, PTGS2 | 5.72881 |
| [MF] GO:0046906 | tetrapyrrole binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGS1, PTGS2 | 5.50409 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13 | 5.47499 |
| [MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGS1, PTGS2 | 5.15324 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD17B1, MAOA, NQO2, PTGS1, PTGS2, XDH | 4.43998 |
| [MF] GO:0048037 | cofactor binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD17B1, NQO2, PTGS1, PTGS2, XDH | 4.43083 |
| [MF] GO:0008144 | drug binding | ACHE, CLK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, DRD1, DRD2, DYRK1A, DYRK1B, DYRK2, DYRK3, HASPIN, NQO2, PIK3CA, PIK3CB, PPARA | 4.41372 |
| [MF] GO:0004712 | protein serine/threonine/tyrosine kinase activity | CLK1, DYRK1A, DYRK1B, DYRK2, DYRK3 | 4.26927 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13 | 4.14686 |
| [MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 3.96336 |
| [MF] GO:0005506 | iron ion binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, XDH | 3.92404 |
| [MF] GO:0008395 | steroid hydroxylase activity | CYP19A1, CYP1A1, CYP2A13, CYP2A6 | 3.14499 |
| [MF] GO:0004666 | prostaglandin-endoperoxide synthase activity | PTGS1, PTGS2 | 2.7343 |
| [MF] GO:0008389 | None | CYP2A13, CYP2A6 | 2.7343 |
| [MF] GO:0009055 | electron transfer activity | AKR1B1, CYP19A1, CYP1A2, NQO2, XDH | 2.58218 |
| [MF] GO:0004674 | protein serine/threonine kinase activity | CLK1, CSNK2A1, DYRK1A, DYRK1B, DYRK2, DYRK3, HASPIN, PIK3CA | 2.2463 |
KEGG Pathways Associated to Targeted Human Proteins
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA5B, CA3, CA5A, CA2, CA4, CA7, CA6, CA9, CA14 | 22.5779 |
| Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, PIK3CA, ADORA1, PIK3CB, PTGS2, PTGS1 | 6.2596 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, CYP1A1, CYP1B1, PTGS2, CYP19A1 | 5.2185 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1, PTGS2 | 5.4256 |
| cAMP signaling pathway_Homo sapiens_hsa04024 | HCAR2, PIK3CA, ADORA1, PIK3CB, DRD1, DRD2, PPARA | 4.7251 |
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 4.9698 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1 | 4.5921 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | PIK3CA, MMP2, PIK3CB, MMP9, ESR1 | 4.0338 |
| Metabolic pathways_Homo sapiens_hsa01100 | FDPS, MAOA, AKR1B1, PTGS2, CYP19A1, PTGS1, CYP2A6, FUT7, HSD17B1, CYP1A2, CYP1A1, ALPL, XDH | 3.7055 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | MAOA, CYP1A2, CYP1A1, CYP1B1 | 4.2198 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | PIK3CA, ADORA3, BCL2, ADORA1, PIK3CB | 3.7055 |
| Pathways in cancer_Homo sapiens_hsa05200 | PIK3CA, MMP1, MMP2, BCL2, PIK3CB, PTGS2, MMP9 | 3.1071 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | PIK3CA, MMP2, BCL2, PIK3CB | 2.8716 |
| Small cell lung cancer_Homo sapiens_hsa05222 | PIK3CA, BCL2, PIK3CB, PTGS2 | 3.1071 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, MMP1, PPARA | 3.4283 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | PIK3CA, MMP2, PIK3CB, MMP9, ESR1 | 2.8105 |
| Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, PIK3CA, BCL2, PIK3CB | 2.8105 |
| TNF signaling pathway_Homo sapiens_hsa04668 | PIK3CA, PIK3CB, PTGS2, MMP9 | 2.8105 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP2A6, CYP1A2, XDH | 5.2185 |
| Leukocyte transendothelial migration_Homo sapiens_hsa04670 | PIK3CA, MMP2, PIK3CB, MMP9 | 2.73 |
| Hepatitis B_Homo sapiens_hsa05161 | PIK3CA, BCL2, PIK3CB, MMP9 | 2.4552 |
| Bladder cancer_Homo sapiens_hsa05219 | MMP1, MMP2, MMP9 | 2.8274 |
| VEGF signaling pathway_Homo sapiens_hsa04370 | PIK3CA, PIK3CB, PTGS2 | 2.4552 |
| cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | PIK3CA, ADORA3, ADORA1, PIK3CB | 2.3017 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | PIK3CA, BCL2, CYP1B1, PTGS2, MMP9 | 2.267 |
| Colorectal cancer_Homo sapiens_hsa05210 | PIK3CA, BCL2, PIK3CB | 2.4552 |
| Cocaine addiction_Homo sapiens_hsa05030 | MAOA, DRD1, DRD2 | 2.7082 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | PIK3CA, PIK3CB, ESR1 | 2.3215 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, PIK3CA, BCL2, PIK3CB | 2.0671 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP2A6, CYP1A2, CYP1A1 | 2.419 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP2A6, MAOA, CYP1A2 | 2.3595 |
| Prostate cancer_Homo sapiens_hsa05215 | PIK3CA, BCL2, PIK3CB | 2.1136 |
| HIF-1 signaling pathway_Homo sapiens_hsa04066 | PIK3CA, BCL2, PIK3CB | 1.9714 |
| Insulin resistance_Homo sapiens_hsa04931 | PIK3CA, PIK3CB, PPARA | 1.914 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, BCL2, PTGS2 | 2.0722 |
| Serotonergic synapse_Homo sapiens_hsa04726 | MAOA, PTGS2, PTGS1 | 1.8928 |
| Toxoplasmosis_Homo sapiens_hsa05145 | PIK3CA, BCL2, PIK3CB | 1.8517 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | PIK3CA, PIK3CB, ESR1 | 1.8517 |
| Platelet activation_Homo sapiens_hsa04611 | PIK3CA, PIK3CB, PTGS1 | 1.833 |
| Neurotrophin signaling pathway_Homo sapiens_hsa04722 | PIK3CA, BCL2, PIK3CB | 1.8422 |
| Dopaminergic synapse_Homo sapiens_hsa04728 | MAOA, DRD1, DRD2 | 1.786 |
| Apoptosis_Homo sapiens_hsa04210 | PIK3CA, BCL2, PIK3CB | 1.719 |
| Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | ADORA3, ADORA1, DRD1, DRD2 | 1.719 |
| Measles_Homo sapiens_hsa05162 | CSNK2A1, PIK3CA, PIK3CB | 1.7421 |
| Hepatitis C_Homo sapiens_hsa05160 | PIK3CA, PIK3CB, PPARA | 1.7592 |
| Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PIK3CA, PIK3CB, PPARA | 1.6796 |
| Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | PIK3CA, BCL2, PIK3CB | 1.6895 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | PIK3CA, BCL2, PIK3CB | 1.6501 |
| Oxytocin signaling pathway_Homo sapiens_hsa04921 | PIK3CA, PIK3CB, PTGS2 | 1.6501 |
| Influenza A_Homo sapiens_hsa05164 | FDPS, PIK3CA, PIK3CB | 1.5604 |
| Alcoholism_Homo sapiens_hsa05034 | MAOA, DRD1, DRD2 | 1.5484 |
| Focal adhesion_Homo sapiens_hsa04510 | PIK3CA, BCL2, PIK3CB | 1.4865 |
| Rap1 signaling pathway_Homo sapiens_hsa04015 | PIK3CA, PIK3CB, DRD2 | 1.4483 |
| HTLV-I infection_Homo sapiens_hsa05166 | FDPS, PIK3CA, PIK3CB | 1.2907 |
| mTOR signaling pathway_Homo sapiens_hsa04150 | PIK3CA, PIK3CB | 1.5604 |
| Endometrial cancer_Homo sapiens_hsa05213 | PIK3CA, PIK3CB | 1.6501 |
| Non-small cell lung cancer_Homo sapiens_hsa05223 | PIK3CA, PIK3CB | 1.6008 |
| Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | PIK3CA, PIK3CB | 1.3128 |
| Glioma_Homo sapiens_hsa05214 | PIK3CA, PIK3CB | 1.5296 |
| Acute myeloid leukemia_Homo sapiens_hsa05221 | PIK3CA, PIK3CB | 1.5936 |
| ErbB signaling pathway_Homo sapiens_hsa04012 | PIK3CA, PIK3CB | 1.3706 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | PIK3CA, PIK3CB | 1.3128 |
| Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | PIK3CA, PIK3CB | 1.3335 |
| Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | PIK3CA, PIK3CB | 1.5339 |
| Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | PIK3CA, PIK3CB | 1.3303 |
| Pancreatic cancer_Homo sapiens_hsa05212 | PIK3CA, PIK3CB | 1.5296 |
| Morphine addiction_Homo sapiens_hsa05032 | ADORA1, DRD1 | 1.3454 |
| Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | PIK3CA, PIK3CB | 1.5239 |
| Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | PIK3CA, PIK3CB | 1.786 |
| PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | PIK3CA, BCL2, PIK3CB | 1.0567 |
| B cell receptor signaling pathway_Homo sapiens_hsa04662 | PIK3CA, PIK3CB | 1.4903 |
| Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.416 |
| Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.4254 |
| Parkinson's disease_Homo sapiens_hsa05012 | DRD1, DRD2 | 1.0933 |
| Choline metabolism in cancer_Homo sapiens_hsa05231 | PIK3CA, PIK3CB | 1.299 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.4097 |
| Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | MMP9 | 0.416 |
| Calcium signaling pathway_Homo sapiens_hsa04020 | DRD1 | 0.416 |
| Osteoclast differentiation_Homo sapiens_hsa04380 | PIK3CA, PIK3CB | 1.127 |
| Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.416 |
| Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | PIK3CA, PIK3CB | 1.3128 |
| Chronic myeloid leukemia_Homo sapiens_hsa05220 | PIK3CA, PIK3CB | 1.4903 |
| Renal cell carcinoma_Homo sapiens_hsa05211 | PIK3CA, PIK3CB | 1.5296 |
| AMPK signaling pathway_Homo sapiens_hsa04152 | PIK3CA, PIK3CB | 1.1663 |
| FoxO signaling pathway_Homo sapiens_hsa04068 | PIK3CA, PIK3CB | 1.1258 |
| Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | PIK3CA, PIK3CB | 1.1188 |
| Melanoma_Homo sapiens_hsa05218 | PIK3CA, PIK3CB | 1.5009 |
| Amoebiasis_Homo sapiens_hsa05146 | PIK3CA, PIK3CB | 1.3019 |
| Amphetamine addiction_Homo sapiens_hsa05031 | MAOA, DRD1 | 1.5296 |
| Central carbon metabolism in cancer_Homo sapiens_hsa05230 | PIK3CA, PIK3CB | 1.5296 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | PIK3CA, PIK3CB | 1.1008 |
| Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | PIK3CA, PIK3CB | 1.2805 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | PIK3CA, PIK3CB | 1.0933 |
| Gap junction_Homo sapiens_hsa04540 | DRD1, DRD2 | 1.3669 |
| Phospholipase D signaling pathway_Homo sapiens_hsa04072 | PIK3CA, PIK3CB | 1.087 |
| Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | PIK3CA, PIK3CB | 1.2907 |
| Inositol phosphate metabolism_Homo sapiens_hsa00562 | PIK3CA, PIK3CB | 1.5009 |
| T cell receptor signaling pathway_Homo sapiens_hsa04660 | PIK3CA, PIK3CB | 1.2907 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.4881 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.4835 |
| Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | PIK3CA, PIK3CB | 0.857 |
| Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | PIK3CA, PIK3CB | 1.4483 |
| Viral carcinogenesis_Homo sapiens_hsa05203 | PIK3CA, PIK3CB | 0.8841 |
| Ras signaling pathway_Homo sapiens_hsa04014 | PIK3CA, PIK3CB | 0.8225 |
| Type II diabetes mellitus_Homo sapiens_hsa04930 | PIK3CA, PIK3CB | 1.6895 |
| Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | PIK3CA, PIK3CB | 1.7176 |
| Arachidonic acid metabolism_Homo sapiens_hsa00590 | PTGS2, PTGS1 | 1.5484 |
| Chemokine signaling pathway_Homo sapiens_hsa04062 | PIK3CA, PIK3CB | 0.9359 |
| Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.6031 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | CYP2A6, XDH | 1.708 |
| Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | PTGS2 | 0.6031 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.6169 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.6162 |
| GnRH signaling pathway_Homo sapiens_hsa04912 | MMP2 | 0.63 |
| Rheumatoid arthritis_Homo sapiens_hsa05323 | MMP1 | 0.6312 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.6321 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.6558 |
| Complement and coagulation cascades_Homo sapiens_hsa04610 | F10 | 0.6718 |
| Leishmaniasis_Homo sapiens_hsa05140 | PTGS2 | 0.694 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.694 |
| Adherens junction_Homo sapiens_hsa04520 | CSNK2A1 | 0.694 |
| Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA | 0.7022 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.7001 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.1136 |
| Renin secretion_Homo sapiens_hsa04924 | ADORA1 | 0.7307 |
| Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | RORC | 0.7282 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B1 | 0.7597 |
| Legionellosis_Homo sapiens_hsa05134 | CLK1 | 0.7844 |
| Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.8114 |
| Arginine and proline metabolism_Homo sapiens_hsa00330 | MAOA | 0.8156 |
| Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.8336 |
| Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | MAOA | 0.8884 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B1 | 0.9838 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.9743 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | MAOA | 0.9355 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B1 | 0.965 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B1 | 0.9281 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.9897 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 1.0273 |
| Circadian rhythm_Homo sapiens_hsa04710 | RORC | 0.9838 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 1.0157 |
| Histidine metabolism_Homo sapiens_hsa00340 | MAOA | 1.0567 |
| Terpenoid backbone biosynthesis_Homo sapiens_hsa00900 | FDPS | 1.0848 |
| Phenylalanine metabolism_Homo sapiens_hsa00360 | MAOA | 1.1578 |
| Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 1.2308 |
Target Exprsssion in Healthy Human Tissues (protein & mRNA level)
Protein expression data was from the "Human Proteome Map" datasetmRNA expression data was from the "GTEx" dataset
Average Target Expression (Fold Change) in Multiple Disease Conditions
Fold Change with Corresponding Normal SamplesClick each cell within the heatmap to access gene expression of individual patient samples